GHTM

Global Health and Tropical Medicine

  • GHTM
    • About GHTM
    • Governance
    • Impact
    • Members
      • Population health, policies and services
        • PPS PhD members
        • PPS non PhD members
      • TB, HIV and opportunistic diseases and pathogens
        • THOP PhD members
        • THOP non PhD members
      • Vector-borne diseases
        • VBD PhD members
        • VBD non PhD members
      • Individual Health Care
        • IHC PhD members
        • IHC non PhD members
      • Tech & Admin support
    • Scientific Advisory Board
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases
      • IHC – Individual health care
    • Research in numbers
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
      • Completed Projects
  • Outreach
    • Events
    • News
    • Policy Support & Community Outreach
  • Publications
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Capacity Building
    • Education
      • Master Theses
      • PhD Theses
    • International
  • Infrastructures
  • Networks & Partnerships
  • Reports
    • GHTM
    • Scientific Advisory Board
    • FCT
Home / Archives for Viveiros M

Spectinamides: a challenge, a proof, and a suggestion

  • Authors: Pieroni M, Viveiros M
  • Publication Year: 2014
  • Journal: Trends in Microbiology
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/24636244

New drugs and shorter regimens are needed to fight resistant forms of tuberculosis. Screening of chemical libraries for mining hit compounds is the common approach to find new antituberculars. A new medicinal chemistry and biology directed research rational has recently been successfully described by Lee and coworkers in Nature Medicine.
Read More

Unraveling Mycobacterium tuberculosis genomic diversity and evolution in Lisbon, Portugal, a highly drug resistant setting

  • Authors: Clark TG, Coll F, Couto I, Hill-Cawthorne GA, Jordao L, Macedo R, Machado D, Mallard K, Maltez F, McNerney R, Pain A, Perdigão J, Portugal I, Silva C, Silva H, Viveiros M
  • Publication Year: 2014
  • Journal: BMC Genomics
  • Link: http://www.biomedcentral.com/1471-2164/15/991

Multidrug- (MDR) and extensively drug resistant (XDR) tuberculosis (TB) presents a challenge to disease control and elimination goals. In Lisbon, Portugal, specific and successful XDR-TB strains have been found in circulation for almost two decades.
Read More

Gold nanoprobes for multi loci assessment of multi-drug resistant tuberculosis

  • Authors: Baptista PV, Couto I, Machado D, Pedrosa P, Veigas B, Viveiros M
  • Publication Year: 2014
  • Journal: Tuberculosis
  • Link: http://www.sciencedirect.com/science/article/pii/S147297921400002X

Here we extend the Au-nanoprobe approach towards discriminating specific mutations within inhA and rpoB genes in PCR amplified DNA from isolates. Using a multiplex PCR reaction for these two genes, it is possible to assess both loci in parallel, and extend the potential of the Au-nanoprobe method to MDRTB molecular characterization with special application in the most frequent Portuguese genotypes.
Read More

Design, synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity

  • Authors: Aires-de-Sousa J, Correia HE, Elvas-Leitao R, Kovalishyn V, Latino DARS, Martins F, Miranda V, Ramos J, Reis M, Santos L, Santos S, Ventura C, Vitorino S, Viveiros M
  • Publication Year: 2014
  • Journal: European Journal of Medicinal Chemistry
  • Link: http://www.sciencedirect.com/science/article/pii/S0223523414004061

The disturbing emergence of multidrug-resistant strains of Mycobacterium tuberculosis(Mtb) has been driving the scientific community to urgently search for new and efficient antitubercular drugs. Despite the various drugs currently under evaluation, isoniazid is still the key and most effective component in all multi-therapeutic regimens recommended by the WHO. This paper describes the QSAR-oriented design, synthesis and in vitro antitubercular activity of several potent isoniazid derivatives (isonicotinoyl hydrazones and isonicotinoyl hydrazides) against H37Rv and two resistant Mtb strains.
Read More

Relatedness of Mycobacterium avium subspecies hominissuis clinical isolates of human and porcine origins assessed by MLVA

  • Authors: Botelho A, Canto A, Couto I, Inácio J, Leao C, Machado D, Sanches IS, Viveiros M
  • Publication Year: 2014
  • Journal: Veterinary Microbiology
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/25085520

In this study, the analysis of Mycobacterium avium tandem repeats (MATRs) loci was adapted to evaluate the genetic diversity of epidemiological unrelated MAH clinical strains of human (n=28) and porcine (n=69) origins, collected from diverse geographical regions across mainland Portugal. These MAH isolates were found to be genetically diverse and genotypes are randomly distributed across the country.
Read More

  • « Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • Next Page »

About GHTM

GHTM is a R&D Unit that brings together researchers with a track record in Tropical Medicine and International & Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal

+351 213 652 600

  • E-mail
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Map

  • Events
  • Research Groups
  • Cross-cutting issues
© Copyright 2025 IHMT-UNL All Rights Reserved.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    UIDB/04413/2020
    UIDP/04413/2020

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok